Monopar reports financial results, raises funds, and advances clinical programs

From GlobeNewswire: 2025-03-31 08:00:00

Monopar Therapeutics Inc. announced their fourth quarter and full-year 2024 financial results, highlighting the in-licensing of ALXN1840 and initiation of Phase 1 clinical trials. ALXN1840, a treatment for Wilson disease, is set to submit an NDA with the FDA in early 2026. Monopar also raised over $55 million in net proceeds in Q4 2024.

Monopar is currently enrolling patients in Phase 1 imaging and therapeutic oncology trials for MNPR-101. The imaging agent MNPR-101-Zr and therapeutic agent MNPR-101-Lu target aggressive cancers expressing uPAR. Positive clinical data for MNPR-101-Zr was presented at EANM 2024, showing uPAR expression in various cancer types.

In Q4 2024, Monopar raised over $55 million in net proceeds through public offerings and private placements. Cash, cash equivalents, and short-term investments as of December 31, 2024, were $60.2 million, expected to fund operations through December 31, 2026. R&D expenses increased significantly in 2024 due to the in-licensing of ALXN1840.

Monopar Therapeutics is a clinical-stage biotechnology company focused on late-stage ALXN1840 for Wilson disease and radiopharma programs targeting advanced cancers. Forward-looking statements include plans to submit an NDA for ALXN1840 in early 2026 and expectations for funding operations through 2026. Monopar continues to advance its pipeline and secure financing for future development.



Read more at GlobeNewswire:: Monopar Reports Fourth Quarter and Full-Year 2024 Financial